Opioid Quota Reform Act

United States115th CongressS-2535Senate
Updated: Jun 19, 2018

Summary

Opioid Quota Reform Act This bill amends the Controlled Substances Act to require the Drug Enforcement Administration (DEA) to consider additional factors—the impact on overall public health and rates of diversion, abuse, and overdose deaths—in setting and adjusting production and manufacturing quotas for fentanyl, oxycodone, hydrocodone, oxymorphone, and hydromorphone. Additionally, if the DEA increases the production quota of fentanyl, oxycodone, hydrocodone, oxymorphone, or hydromorphone, then it must explain why the public health benefits of increasing the quota outweigh the consequences of potential diversion.

Bill texts

Available versions
View official text

2 versions available

All available records shown.

Timeline

  1. Introduced in Senate

  2. Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.

    Senate

  3. Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.

    Senate

  4. Placed on Senate Legislative Calendar under General Orders. Calendar No. 473.

    Senate